AUSTAR
奥 星

Austar Lifesciences Limited
奧星生命科技有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 6118)

UPDATE ON FINANCIAL INFORMATION

This announcement is made by Austar Lifesciences Limited ("**Company**" and together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited ("**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules).

The board ("**Board**") of directors ("**Directors**", each a "**Director**") of the Company wishes to inform the shareholders of the Company and potential investors that, based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2026 and the information currently available to the Board, it is expected that a profit attributable to the owners of the Company of approximately RMB8 million to RMB10 million for the six months ended 30 June 2026 will be recorded, as compared with a profit attributable to the owners of the Company of approximately RMB25 million for the six months ended 30 June 2025.

The decrease in the profit attributable to the owners of the Company for the six months ended 30 June 2026 was mainly attributable to:

(i) the absence of the one-off non-operating exchange gains of approximately RMB11.4 million recorded for the six months ended 30 June 2025;

(ii) compression of gross margins due to the execution of certain strategic projects; and

(iii) higher operating expenses incurred for market promotion amid the Group's accelerated market expansion.

The Group is still in the process of finalising its interim results for the six months ended 30 June 2026. The information contained in this announcement is solely based on the preliminary assessment by the management of the Company of the information currently available to the Group, including the unaudited consolidated management accounts of the Group for the six months ended 30 June 2026 which have not been reviewed by the Company's auditors or the audit committee of the Board and may be subject to adjustments. Details of the Group's financial information and performance will be disclosed in its interim results for the six months ended 30 June 2026, which are expected to be announced in late August 2026.

Shareholders of the Company and potential investors should exercise caution when dealing in the shares of the Company.

On behalf of the Board
Austar Lifesciences Limited
Ho Kwok Keung, Mars
Chairman and Chief Executive Officer

Hong Kong, 30 July 2026

As at the date of this announcement, the Board comprises four executive Directors, namely Mr. Ho Kwok Keung, Mars, Mr. Ho Kin Hung, Madam Zhou Ning and Mr. Bian Ce; one non-executive Director, namely Madam Ji Lingling; and three independent non-executive Directors, namely Mr. Cheung Lap Kei, Madam Chiu Hoi Shan and Mr. Leung Oi Kin.